Capecitabine (Xeloda)

DRUG14 trials

Conditions

AdenocarcinomaAdenocarcinoma Clear CellBreast CancerC04.588.274.476.411.307Cancer of LiverCarcinoma, Squamous CellColorectal CancerEsophageal Cancer

Phase 1

Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer

CompletedNCT00153881

Dartmouth-Hitchcock Medical CenterEsophageal Neoplasms

Start: 2000-02-29End: 2013-09-30Updated: 2014-11-13

Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma

TerminatedNCT00216437

James A. Haley Veterans Administration HospitalCancer of Liver

Start: 2004-12-31End: 2007-03-31Target: 30Updated: 2007-11-12

Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer

CompletedNCT00316420

Swedish Medical CenterPancreatic Cancer

Start: 2003-12-31End: 2009-08-31Updated: 2010-03-08

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

TerminatedNCT00354523

M.D. Anderson Cancer CenterSolid Tumor, Thyroid Cancer

Start: 2004-12-31End: 2013-08-31Updated: 2014-12-17

Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer

TerminatedNCT00368329

Stanford UniversityAdenocarcinoma, Carcinoma, Squamous Cell, Esophageal Cancer +1

Start: 2006-06-30End: 2009-03-31Updated: 2012-07-16

Phase 2

Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer

CompletedNCT00203411

Translational Oncology Research InternationalColorectal Cancer

Start: 2006-03-31End: 2011-03-31Updated: 2017-02-06

XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer

CompletedNCT00212615

Odense University HospitalC04.588.274.476.411.307

Start: 2004-02-29End: 2008-10-31Updated: 2020-11-06

Immunochemotherapy for Metastatic Renal Cell Carcinoma

NCT00226798

Rambam Health Care CampusAdenocarcinoma Clear Cell

Start: 2003-12-31End: 2005-09-30Target: 45Updated: 2006-01-04

Xeloda and Bevacizumab to Treat Rectal Cancer

CompletedNCT00847119

Institut Català d'OncologiaRectal Cancer

Start: 2007-09-30End: 2015-02-28Updated: 2017-08-29

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

TerminatedNCT07012330

Erasmus Medical CenterNeuroendocrine (NE) Tumors

Start: 2007-03-01End: 2015-12-31Updated: 2025-06-10

Phase 3

Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

TerminatedNCT00440622

Hellenic Oncology Research GroupBreast Cancer

Start: 2003-04-30End: 2008-11-30Updated: 2013-02-13

Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer

CompletedNCT01308190

Corporacion Parc TauliRectal Cancer

Start: 2010-08-31End: 2021-10-31Updated: 2021-11-23

Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)

Not yet recruitingNCT06450574

Corporacion Parc TauliRectal Cancer Stage I

Start: 2024-10-31End: 2027-10-31Target: 106Updated: 2024-06-10

Phase 4

Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma

TerminatedNCT00216424

James A. Haley Veterans Administration HospitalColorectal Cancer

Start: 2005-02-28End: 2007-01-31Target: 40Updated: 2007-11-12

2025-07-015 citations

Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).

2022-10-0841 citations

Noninferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 (T2T3sN0M0) undergoing neoadjuvant treatment and local excision (TEM) versus total mesorectal excision (TME): Preoperative, surgical, and pathological outcomes—The TAUTEM-study.

Journal of Clinical Oncology2022-06-014 citations

Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2-T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME).

2017-12-1221 citations

Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer.

2015-02-2617 citations

A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.

2014-08-0215 citations

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.

2013-07-1762 citations